Sunday, March 22

Healthcare

Psyence Biomedical to acquire drug developer Clairvoyant

09/07/20241 Min Read

acquire Biomedical Clairvoyant developer drug Psyence

Previous ArticleAfya announces MEC decision on medical seats reconsideration

Next Article Organon downgraded, Amneal upgraded as J.P. Morgan reviews specialty pharma